ArticleJournal of gynecologic oncology2018
Retrospective analysis of sites of recurrence in stage I epithelial ovarian cancer.
Article in Journal of gynecologic oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- The impact of lymphadenectomy on ovarian clear cell carcinoma: a systematic review and meta-analysis.World journal of surgical oncology · 2024Pooled it
- Pattern of ovarian cancer recurrence and survival: final analysis of an extended cohort of 591 patients.Wiener medizinische Wochenschrift (1946) · 2026Article
- Effects of Clinical Covariates on Serum miRNA Expression among Women without Ovarian Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Frequency of thoracic recurrence based on pathological features in patients with ovarian epithelial tumors in stage I versus higher stages.Japanese journal of radiology · 2023Article
- The prognostic role of systemic inflammatory markers in apparent early-stage ovarian cancer.International journal of clinical oncology · 2023Observational
- Impact of incomplete surgery and adjuvant chemotherapy for the intraoperative rupture of capsulated stage I epithelial ovarian cancer: a multi-institutional study with an in-depth subgroup analysis.Journal of gynecologic oncology · 2021Article
- A large-scale multi-institutional study evaluating prognostic aspects of positive ascites cytology and effects of therapeutic interventions in epithelial ovarian cancer.Scientific reports · 2021Article
- Introduction of rectosigmoid colectomy improves survival outcomes in early-stage ovarian cancer patients.International journal of clinical oncology · 2021Article
- Metastatic brain disease in early stage ovarian cancer: A case report.Gynecologic oncology reports · 2020Article
- Left Supraclavicular Lymph Node Metastasis from Ovarian Cancer Associated with Papillary Thyroid Microcarcinoma, a Confusing Pathology-Essential Role of Functional Imaging.Diagnostics (Basel, Switzerland) · 2020Article
- Reducing Ovarian Cancer Mortality Through Early Detection: Approaches Using Circulating Biomarkers.Cancer prevention research (Philadelphia, Pa.) · 2020Review
- Rethinking of treatment strategies and clinical management in ovarian clear cell carcinoma.International journal of clinical oncology · 2020Review
- Tryptophan catabolism in epithelial ovarian carcinoma.Trends in cancer research · 2019Article
- Molecular Mechanisms Regulating Organ-Specific Metastases in Epithelial Ovarian Carcinoma.Cancers · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of the study is to investigate recurrence of stage I epithelial ovarian cancer.
methodsSix hundred two patients diagnosed with stage I epithelial ovarian cancer at 4 hospitals between 2000 and 2013 were retrospectively analyzed. Age, surgical procedure, substage, histologic type, adjuvant chemotherapy, recurrence, initial recurrence site (peritoneal dissemination [P], hematogenous recurrence [H], lymphogenous recurrence [L], and others [O]), and frequency of recurrence at each site were investigated retrospectively.
resultsMedian age was 54 years and median follow-up was 60 months. The stage was IA in 180 cases (30%), IB in 8 (1%), IC1 in 247 (41%), IC2 in 63 (10%), and IC3 in 104 (17%). Systematic lymph node dissection including both pelvic and para-aortic lymph nodes was performed in 224 patients (37%), and 412 patients (68%) received adjuvant chemotherapy. Recurrence occurred in 70 patients (11.6%). The median time to recurrence was 18 months, and the stage was IA in 13 (19%), IB in 1 (1%), IC1 in 24 (34%), IC2 in 9 (13%), and IC3 in 23 (33%) cases. The numbers of recurrence at the P, H, L, and O sites, including overlapping cases, were 49 (70%), 18 (26%), 9 (13%), and 6 (9%), respectively, and recurrence by peritoneal dissemination in the pelvis occurred in 43 cases (61%).
conclusionRecurrence of stage I epithelial ovarian cancer by peritoneal dissemination was frequent, especially in the pelvis. There is a need to elucidate the pathogenesis of peritoneal recurrence and to prepare a treatment strategy to prevent pelvic peritoneal recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.